IP Library Granted Patent US 8,685,926
Granted Patent B2
US 8,685,926 · App. 13/181,373 · Granted Apr 1, 2014

Compositions and method for CaMKII inhibitors and uses thereof

Inventors: K. Ulrich Bayer (Denver, CO); Steve Coultrap (Denver, CO)
Assignee: The Regents of the University of Colorado, a body corporate
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,926
App. No.
13/181,373
Granted
Apr 1, 2014
Kind
B2
Abstract

Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.

Claims (11)

1. A pharmaceutical composition comprising a peptide comprising Lys Arg Ala Pro Lys Leu Gly Gln Ile Gly Arg Val Lys Ala Val Val Ile Glu Asp (SEQ ID NO:23); and a pharmaceutically acceptable derivative or salt thereof.

2. The composition of claim 1 , further comprising a cell-transfer/penetrating agent associated with the peptide.

3. The composition of claim 2 , wherein the cell-transfer/penetrating agent is fused to the amino acid sequence.

4. The composition of claim 2 , wherein the cell-transfer/penetrating agent comprises tat, ant, meristyl-group, palmityl-group or combination thereof.

5. The composition of claim 2 , further comprising one or more agents for treating a neurodegenerative condition.

6. A pharmaceutical composition comprising a peptide comprising, Lys Arg Ala Pro Lys Leu Gly Gln Ile Gly Arg Gln Lys Ala Val Asp Ile Glu Asp (SEQ ID NO:24); and a pharmaceutically acceptable derivative or salt thereof.

7. The composition of claim 6 , further comprising a cell-transfer/penetrating agent associated with the peptide.

8. A kit comprising:

a vessel; and

one or more compositions comprising at least one peptide comprising, Lys Arg Ala Pro Lys Leu Gly Gln Ile Gly Arg Gln Lys Ala Val Asp Ile Glu Asp (SEQ ID NO:24) and Lys Arg Ala Pro Lys Leu Gly Gln Ile Gly Arg Val Lys Ala Val Val Ile Glu Asp (SEQ ID NO:23).

9. The kit of claim 8 , further comprising a delivery device for administering the one or more compositions to a subject.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 24, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044709/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: BAYER, K. ULRICH; COULTRAP, STEVE
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 027008/0086 →
Continuity (4)
Continuation In Part 12679459
Provisional Application 60980766 · Oct 17, 2007
Provisional Application 60975329 · Sep 26, 2007
Related Publication 20120015885A1 · Jan 19, 2012